BioInvent International AB (publ) (BINVS.XC)
Cboe UK - Cboe UK Real-time price. Currency in SEK
Add to watchlist
As of 04:06PM BST. Market open.
| Previous close | 28.50 |
| Open | 29.90 |
| Bid | 27.10 x N/A |
| Ask | 0.00 x N/A |
| Day's range | 27.45 - 29.90 |
| 52-week range | 27.45 - 34.75 |
| Volume | |
| Avg. volume | 0 |
| Market cap | 1.843B |
| Beta (5Y monthly) | 0.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.76 |
| Earnings date | 29 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireCASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a biopharmaceutical company specializing in the development and commercialization of innovative therapeutic and pharmaceutical products, and BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announced preliminary encouraging efficacy data for BI-1206 in combination with rituximab in patients
© 2024 Yahoo. All rights reserved.